57543-70-1

Usage

Uses

Used in Organic Synthesis:
7-Methoxy-2H-chromene-3-carbonitrile is used as a key intermediate in the synthesis of various organic compounds due to its unique structure and reactivity. Its presence in the synthesis process can lead to the development of new molecules with potential applications in different fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 7-Methoxy-2H-chromene-3-carbonitrile is utilized as a building block for the design and synthesis of novel drug candidates. Its biological properties and structural features make it a promising compound for the development of pharmaceutical products with potential therapeutic effects.
Used in Drug Development:
7-Methoxy-2H-chromene-3-carbonitrile is employed as a potential drug candidate in the pharmaceutical industry. Its unique structure and biological properties allow for the exploration of its therapeutic potential in treating various diseases and conditions.
Used in Fluorescent Probe Development:
In the field of biochemical assays, 7-Methoxy-2H-chromene-3-carbonitrile is used as a component in the development of fluorescent probes. Its chromene core offers the potential for creating probes that can be used in various biological and chemical analyses, enhancing the understanding of biological processes and interactions.
Used in Biochemical Assay Materials:
7-Methoxy-2H-chromene-3-carbonitrile is utilized in the creation of materials for biochemical assays, such as sensors and imaging agents. Its unique properties and reactivity contribute to the development of innovative tools for studying biological systems and detecting specific molecules or interactions.

InChI:InChI=1S/C11H9NO2/c1-13-10-3-2-9-4-8(6-12)7-14-11(9)5-10/h2-5H,7H2,1H3

Upstream product

• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 107-13-1 acrylonitrile 
• 108-46-3 recorcinol 
• 95-01-2 2,4-Dihydroxybenzaldehyde 

Downstream Products

• 57543-60-9 acide methoxy-7 2H chromene carboxylique-3 
• 76322-24-2 7-methoxychroman-3-one 
• 1195865-08-7 (Z)-3-ethoxymethyl-7-methoxy-2-phenylimino-2H-chromene 

Relevant academic research and scientific papers

A spectroscopic insight into the interaction of chromene 1,2,4-oxadiazole-based compounds with bovine serum albumin

Four synthesized 2H-chromene-based 1,2,4-oxadiazole compounds (6a-6d) were studied for binding with bovine serum albumin (BSA) by different spectroscopic and thermodynamic analyses. A molecular docking program was used to find out the possible binding sites and binding affinity of 2H-chromene based 1,2,4-oxadiazole compounds with bovine serum albumin (BSA). The intrinsic fluorescence of BSA was quenched by these compounds through static quenching mechanism, and the estimated binding constant (Kb) value was found to be 1.5 × 103–10 × 103. The conformational changes of BSA were monitored by circular dichroism analysis, and it was observed that BSA is structurally stable in the presence of these compounds. The thermodynamic results indicated that the interaction process is spontaneous and the binding between oxadiazole compounds and BSA is mainly driven by hydrogen bonding and van der Waals forces. This study would be helpful to understand the biological benefits of oxadiazole-based compounds as well as the nature of interactions with biomolecules. Graphic abstract: [Figure not available: see fulltext.].

Benzopyran compounds and preparation method thereof as well as pharmaceutical composition and use of benzopyran compounds

The invention discloses benzopyran compounds as shown in a formula I, a preparation method of the benzopyran compounds, a composition containing the compounds, and use of the compounds in preparation of a farnesoid X receptor antagonist, a liver protection agent and medicines for preventing and treating hyperlipidemia and diabetes mellitus type II.

One pot, three component 1,3 dipolar cycloaddition: Regio and diastereoselective synthesis of spiropyrrolidinyl indenoquinoxaline derivatives

A competent and highly discriminating one-pot synthesis of highly diversified novel functionalized indenoquinoxalone grafted spiropyrrolidine linked chromene-3-carbonitrile conjugates accumulating three pharmocophoric cores, heterocyclic indenoquinoxalone, pyrrolidines and chromene-3-carbonitrile in a single molecular framework by means of 1,3-dipolar cycloaddition reaction between indenoquinoxalone, proline/benzyl amine and chromene-3-carbonitrile in ethanol under classical and microwave conditions is described. The three component 1,3-dipolar cycloaddition reaction proceeds via in situ generation of azomethine ylides by the decarboxylative condensation of indenoquinoxalone with proline/benzyl amine and their selectivity towards the endo cyclic double bonds of dipolarophile (chromene-3-carbonitrile) leading to the formation of highly functionalised regio- and diastereoselective molecular hybrids. This methodology exemplifies the green chemistry protocol such as mild reaction conditions, high yields, one-pot procedure and operational simplicity.

Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists

Farnesoid X receptor (FXR), a nuclear receptor mainly distributed in liver and intestine, has been regarded as a potential target for the treatment of various metabolic diseases, cancer and infectious diseases related to liver. Starting from two previously identified chalcone-based FXR antagonists, we tried to increase the activity through the design and synthesis of a library containing chalcones, flavones and chromenes, based on substitution manipulation and conformation (ring closure) restriction strategy. Many chalcones and four chromenes were identified as microM potent FXR antagonists, among which chromene 11c significantly decreased the plasma and hepatic triglyceride level in KKay mice.

Rational design and synthesis of novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent

Based on earlier proven pharmacophore analogues of cancer a novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazoles (13-16) were rationally designed and synthesized by the reaction of chromene-3-carboxylic acids (10a-d) with substituted acyl bromides in the presence of TEA followed by refluxing with NH4OAc in toluene. Compounds 13-16 were screened in vitro for the inhibition of KRAS/Wnt and their anti-angiogenesis properties. Compound 16f has been identified as a potent anti-angiogenesis molecule, which can be considered as a new lead structure. The molecular docking analysis displayed the higher binding affinity of 16f with KRAS, Wnt and VEGF.

METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND

Disclosed herein is a method for preparing a coumarin compound of formula (F), in which R1, R2, and R3 are independently H, C1?C7 alkoxy, C1?C7 alkyl, phenoxy, benzyloxy, or a ha

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR

The present invention relates to aromatic compounds of the formula (I), wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; Y is O, S, -CH=N-, -CH=CH- or -N=CH-; A is CH2i O or S; E is CR6R7 or NR 3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4--alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4--alkenyl, formyl or C,-C3-alkylcarbonyl; R1a is H, C2-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4 -cycloalkyl, or R1a and R2 together are (CH2)n with n being 2 or 3, or R1a and R2a together are (CH2)n with n being 2 or 3; R2 and R2a are independently of each other H, CH3, CH2F, CHF2 or CF3; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, C1-C2-alkyl and fluorinated C1-C2-alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

Conformationally restricted anti-plasmodial chalcones

Chalcones can exist as Z- or E-isomers and it is generally anticipated that both isomers are equipotent. In order to determine the active isomer of anti-plasmodial chalcones a series of analogues locked in the Z- or the E-form were prepared and evaluated